Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease

Keyphrases

• Parkinson's Disease Model 100%
• Mouse Model 100%
• D3 Receptor 100%
• Dopamine D3 Receptor 100%
• 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 100%
• Levodopa Therapy 100%
• Probenecid 100%
• Levodopa 44%
• Dorsal Striatum 33%
• DRD3 33%
• Mitogen-activated Protein Kinase 22%
• Receptor-interacting Protein Kinase 1 (RIPK1) 22%
• Receptor Expression 22%
• Signal Functions 22%
• Dyskinesia 22%
• EGFP Mice 22%
• Cellular Level 11%
• Parkinson's Disease 11%
• Reporter Mice 11%
• Antipsychotics 11%
• Receptor Function 11%
• Signaling Molecules 11%
• Receptor Signaling 11%
• Bradykinesia 11%
• Locomotor Activity 11%
• Treatment Duration 11%
• Western Blot Analysis 11%
• Chronic Treatment 11%
• Twice Daily 11%
• Tardive Dyskinesia 11%
• Akinesia 11%
• GFP Reporter 11%
• Motor Side Effects 11%

Neuroscience

• Parkinson's Disease 100%
• Dopamine Receptor D3 100%
• L-DOPA 100%
• Tetrahydropyridine 100%
• Receptor 100%
• Probenecid 100%
• Dorsal Striatum 42%
• Mitogen-Activated Protein Kinase 28%
• Receptor Expression 28%
• Mitochondrial Permeability Transition Pore 28%
• Dyskinesia 28%
• Receptor Protein 14%
• Bradykinesia 14%
• Agonist 14%
• Locomotor Activity 14%
• Western Blot 14%
• Akinesia 14%
• Tardive Dyskinesia 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse Model 100%
• Receptor 100%
• Parkinson's Disease 100%
• Dopamine 3 Receptor 100%
• 1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine 100%
• Levodopa 100%
• Probenecid 100%
• Side Effect 22%
• Mitogen Activated Protein Kinase 22%
• Dyskinesia 22%
• Mitochondrial Permeability Transition Pore 22%
• Western Blot 11%
• Receptor Protein 11%
• Bradykinesia 11%
• Tardive Dyskinesia 11%
• Akinesia 11%
• Table Salt 11%